Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)
Conditions
Interventions
Intervention1: Terminalia bellerica 2000mg/day: 2 capsules of 500 mg given orally twice a day after food
(total dose of 2000mg/day Terminalia bellerica)
Intervention2: Terminalia bellerica 1000mg/day:
Sponsors
Dr K Niranjan
Eligibility
Inclusion criteria
Inclusion criteria: 1.Either gender, between the ages of 18 and 69 years. 2.Serum uric acid level >= 6.0 mg/dL and 3.Serum creatinine >=1.5mg/dl to 4. Ability to comply with the requirements of the study and to give voluntary, written informed consent and willing to come for regular follow up visits.
Exclusion criteria
Exclusion criteria: 1.Presence of a gout flare during screening or baseline visit. 2.Patients currently using aspirin or other NSAIDS, diuretics, steroids, immunosuppressants, other medications with known urate-lowering effects. 3.History or presence of nephrolithiasis. 4.Patients who had undergone renal transplantation. 5.Known liver, thyroid or infectious diseases. 6.Uncontrolled hypertension or diabetes, severe hepatic impairment. 7.Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant). 8.Chronic alcoholics and patients with history or suspicion of drug abuse. 9.Known hypersensitivity to any drugs or their constituents. 10.Pregnant or lactating females. 11.Patients currently on alternative system of medicine. 12.Participation within 30 days prior to screening in another investigational
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Absolute change in serum creatinine and eGFR levels from baseline to the end of 24 weeks of treatment. 2.Mean percentage reduction in serum creatinine and eGFR levels from baseline to the end of 24 weeks of treatment. Timepoint: 0, 4, 8, 12, 16, 20, 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Absolute change in serum uric acid levels from baseline to the end of 24 weeks of treatment. 2.Mean percentage reduction in serum uric acid levels from baseline to the end of 24 weeks of treatment. Timepoint: 0, 4, 8, 12, 16, 20, 24 weeks | — |
Countries
India
Contacts
Public ContactDr P USHARANI
NIZAMS INSTITUTE OF MEDICAL SCIENCES
Outcome results
None listed